{"article_title": "Gary Pisano: Big Pharma Needs to Get Busy in the Lab", "article_keywords": ["pharmacyclics", "billion", "needs", "busy", "pharma", "purchased", "big", "study", "companies", "say", "lab", "single", "drug", "pisano", "gary", "reached", "tufts"], "article_url": "http://www.wsj.com/articles/gary-pisano-big-pharma-needs-to-get-busy-in-the-lab-1426805547", "article_text": "The average cost of developing a single new drug has reached $2.6 billion, according to a 2014 study by the Tufts Center for the Study of Drug Development. Is this figure accurate? It depends who you ask: Critics of the drug industry say companies use the expense numbers to justify high prices. But drug companies defend the estimates.\n\nA March 4 event offered a new data point. The biotech firm Pharmacyclics agreed to be purchased by drug maker AbbVie for $21 billion after a heated bidding process. Pharmacyclics has one...", "article_metadata": {"article.template": "snippet", "article.created": "2015-03-19T22:52:00.000Z", "article.section": "Opinion", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "In The Wall Street Journal, Gary Pisano writes that blanket generalizations about biotech firms being more efficient are unfounded.", "title": "Big Pharma Needs to Get Busy in the Lab", "image": {"src": "https://si.wsj.net/public/resources/images/BN-HM892_pisano_G_20150319170749.jpg", "alt": "Big Pharma Needs to Get Busy in the Lab", "identifier": "https://si.wsj.net/public/resources/images/BN-HM892_pisano_D_20150319170749.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB11054895691343723447204580511641309740982&headline=Big%20Pharma%20Needs%20to%20Get%20Busy%20in%20the%20Lab&weburl=http://www.wsj.com/articles/SB11054895691343723447204580511641309740982"}}, "page.site.product": "WSJ", "keywords": "AbbVie,ABBV,Pharmacyclics,PCYC,biotechnology,political,general news,sciences,technologies,commentaries,opinions,pharmaceuticals,health care,life sciences,medical research services,healthcare support services,medical,clinical,diagnostic services", "news_keywords": "AbbVie,ABBV,Pharmacyclics,PCYC,biotechnology,political,general news,sciences,technologies,commentaries", "article.headline": "Big Pharma Needs to Get Busy in the Lab", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-HM892_pisano_E_20150319170749.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-HM892_pisano_D_20150319170749.jpg"}}, "description": "In The Wall Street Journal, Gary Pisano writes that blanket generalizations about biotech firms being more efficient are unfounded.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB11054895691343723447204580511641309740982&headline=Big%20Pharma%20Needs%20to%20Get%20Busy%20in%20the%20Lab&weburl=http://www.wsj.com/articles/SB11054895691343723447204580511641309740982", "user.type": "nonsubscriber", "article.page": "Opinion", "page.content.format": "responsive", "article.summary": "In The Wall Street Journal, Gary Pisano writes that blanket generalizations about biotech firms being more efficient are unfounded.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-03-19T22:52:00.000Z", "dj.asn": "i-43d2", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "image_count": 1, "word_count": 668}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "In The Wall Street Journal, Gary Pisano writes that blanket generalizations about biotech firms being more efficient are unfounded.", "title": "Big Pharma Needs to Get Busy in the Lab", "url": "http://www.wsj.com/articles/gary-pisano-big-pharma-needs-to-get-busy-in-the-lab-1426805547", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-HM892_pisano_G_20150319170749.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Gary Pisano", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Big Pharma Needs to Get Busy in the Lab", "article.type": "Commentary (U.S.)", "article.id": "SB11054895691343723447204580511641309740982", "user.exp": "default", "article.updated": "2015-03-19T22:52:00.000Z"}, "_id": "\"57477af46914bd0286fd9bf2\"", "article_summary": "It depends who you ask: Critics of the drug industry say companies use the expense numbers to justify high prices.\nBut drug companies defend the estimates.\nThe biotech firm Pharmacyclics agreed to be purchased by drug maker AbbVie for $21 billion after a heated bidding process.\nThe average cost of developing a single new drug has reached $2.6 billion, according to a 2014 study by the Tufts Center for the Study of Drug Development.\nPharmacyclics has one..."}